1. Home
  2. DFH vs NUVB Comparison

DFH vs NUVB Comparison

Compare DFH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dream Finders Homes Inc.

DFH

Dream Finders Homes Inc.

HOLD

Current Price

$13.96

Market Cap

1.7B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.87

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFH
NUVB
Founded
2008
2018
Country
United States
United States
Employees
N/A
291
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
DFH
NUVB
Price
$13.96
$4.87
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$26.00
$11.38
AVG Volume (30 Days)
603.6K
3.1M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.14
N/A
Revenue
$4,322,848,000.00
N/A
Revenue This Year
$0.81
$205.55
Revenue Next Year
$7.82
$58.57
P/E Ratio
$6.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.29
$1.57
52 Week High
$31.10
$9.75

Technical Indicators

Market Signals
Indicator
DFH
NUVB
Relative Strength Index (RSI) 41.06 57.00
Support Level $13.35 $4.06
Resistance Level $14.75 $5.55
Average True Range (ATR) 0.75 0.24
MACD 0.18 0.10
Stochastic Oscillator 40.51 97.11

Price Performance

Historical Comparison
DFH
NUVB

About DFH Dream Finders Homes Inc.

Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: